HIV Drug Showdown: New Regimens vs. Old

Big news for HIV treatment in China: Newer INSTI-based regimens (like Biktarvy) are just as effective and safe as the old standard, but they’re better for drug resistance and sticking to your meds. The catch? They’re cost-effective for patients but not for the healthcare system (unless prices drop). If you’re weighing options or watching policy shifts, this could shake up first-line HIV care soon! #HIVTreatment #HealthNews #Pharma #ChinaHealth #CostEffectiveness #Health